MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals is a promising biopharmaceutical company with a positive outlook due to their strong pipeline of rare and orphan disease treatments, including their main product Livmarli. With strong efficacy and a clean safety profile seen in their AZURE-1 trial, which is on track for a 3Q readout, and complementary AZURE-4 data expected in 4Q, Mirum is poised to have a potentially successful NDA submission. They also have a large, untapped market for their rare disease treatments and a strong financial outlook with their current approved medicines and potential for peak revenue of over $750 million for Livmarli alone.

Mirum Pharmaceuticals is facing significant challenges in obtaining further approvals for its pipeline candidates, with ongoing clinical and regulatory risks. While the company has a strong portfolio of rare disease treatments, the lack of approved therapies for these indications and the need for additional clinical data present potential financial and commercial risks. Despite strong commercial performance in its current products, the recent setback in PSC and FDA's request for a Phase 3 trial may delay future revenue growth, impacting the company's path to profitability. As a result, the analyst maintains a negative outlook on Mirum's stock.